Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
ACAD Stock Chart & Stats
$20.36
-$0.09(-0.52%)
At close: 4:00 PM EST
$20.36
-$0.09(-0.52%)
Day’s Range― - ―
52-Week Range$13.40 - $26.65
Previous CloseN/A
Volume443.16K
Average Volume (3M)2.22M
Market Cap
$3.38B
Enterprise Value$2.93B
Total Cash (Recent Filing)$762.00M
Total Debt (Recent Filing)$44.60M
Price to Earnings (P/E)15.1
Beta1.18
Next Earnings
Nov 11, 2025EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding168,712,220
10 Day Avg. Volume1,999,981
30 Day Avg. Volume2,221,268
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue2.88
Enterprise Value/Gross Profit3.13
Enterprise Value/Ebitda27.59
Forecast
1Y Price Target
$29.41Price Target Upside44.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Bulls Say, Bears Say
Bulls Say
Buy RecommendationAnalyst reiterates a BUY recommendation for ACAD, emphasizing that the stock remains undervalued based on its two currently approved and marketed products, Nuplazid and Daybue.
Financial StabilityACAD had ~$762 million in cash at the end of 2Q25, with no imminent need to raise capital, highlighting financial stability.
Product PerformanceNuplazid's recent performance has been encouraging, with management raising the low end of its 2025 sales outlook, and Daybue showing growth in patient uptake and steady long-term patient persistency rates.
Bears Say
Clinical Trial FailureThe PWS study evaluating ACP-101 in patients with hyperphagia in Prader-Willi syndrome failed to demonstrate a significant benefit on the primary and secondary endpoints.
Discontinued DevelopmentThe management does not plan to further investigate ACP-101 for the treatment of Prader-Willi syndrome.
Pipeline SetbackACP-101's Phase 3 COMPASS PWS trial failed to meet its primary endpoint, showing no separation from placebo on secondary endpoints.
ACADIA Pharmaceuticals News
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $13.40 and its highest was $26.65 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $3.38B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Nov 11, 2025 which is in 27 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Aug 06, 2025. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.138 by $0.022.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is 0.14.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 168,712,220 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.16 in its last earnings report, beating expectations of $0.138. Following the earnings report the stock price went up 2.521%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Currently, no hedge funds are holding shares in ACAD
ACADIA Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.41 (44.45% Upside)
$29.41 (44.45% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 444.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $41.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.45%
12-Months-Change
Fundamentals
Return on Equity
33.18%
Trailing 12-Months
Asset Growth
34.07%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. The company is primarily engaged in the research and development of drugs for the treatment of conditions such as Parkinson's disease psychosis and schizophrenia. Its core product, NUPLAZID (pimavanserin), is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis and is marketed in the United States.
ACAD Company Deck
ACAD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, with strong financial performance, significant growth in DAYBUE and NUPLAZID sales, and a robust pipeline expansion. However, increased SG&A expenses and challenges in clinical trials were noted as areas of concern.View all ACAD earnings summariesACAD Stock 12 Month Forecast
Average Price Target
$29.41
▲(44.45% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
PTC Therapeutics
―
Krystal Biotech
―
MoonLake Immunotherapeutics
―
Arcellx Inc
―
Ownership Overview
23.64% Insiders
15.71% Mutual Funds
0.02% Other Institutional Investors
35.56% Public Companies and Individual Investors